UNSPSC 51201500: Immunosuppressants

This classification denotes agents that suppress immune function by one of several mechanisms of action. classical cytotoxic immunosuppressants act by inhibiting dna synthesis. others may act through activation of t-cells or by inhibiting the activation of helper cells. while immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of interleukins and other cytokines are emerging.

UNSPSC 51201500 Immunosuppressants is a Class code, but the three recent state and local opportunities tagged under it show minimal alignment with pharmaceutical immunosuppressant products. The City of Tucson's May 2026 RFP solicits athletic training services (injury prevention, rehabilitation, and return-to-duty support) for fire and police personnel; the City of Tampa's April 2026 ITB targets first-aid and medical supplies (antiseptics, pain relievers, bandages, emergency blankets) for the Fire Rescue Department; and the Texas Health and Human Services Commission's April 2026 RFI explores direct-to-manufacturer prescription programs without specifying immunosuppressants. None of these solicitations concern immunosuppressant medications. The code shows little relevant recent activity in state and local procurement.

The geographic spread across the sample includes Arizona (Tucson), Florida (Tampa), and Texas, but the mismatch between the code's nominal scope and the work actually being solicited indicates that either the tagging is incorrect or the code is not currently a significant procurement driver for state and local buyers. The Tucson athletic training RFP (due June 9, 2026) and Tampa first-aid supplies ITB (opened April 9, 2025) represent active issuing bodies in their respective jurisdictions, but neither procurement involves pharmaceutical products, let alone immunosuppressants. A business development firm evaluating this code should verify whether state and local health agencies, medicaid programs, or hospital systems are using the code for actual immunosuppressant acquisitions, as the current opportunity sample does not support active market demand under the nominal scope.